The Role of Serine Peptidase Inhibitor Kazal Type 13 (SPINK13) as a Clinicopathological and Prognostic Biomarker in Patients with Clear Cell Renal Cell Carcinoma

Wen-Hao Xu; Shen-Nan Shi; Jun Wang; Yue Xu; Xi Tian; Fang-Ning Wan; Da-Long Cao; Yuan-Yuan Qu; Hai-Liang Zhang; Ding-Wei Ye

doi:10.12659/MSM.917754

11 December 2019 : Clinical Research

The Role of Serine Peptidase Inhibitor Kazal Type 13 (SPINK13) as a Clinicopathological and Prognostic Biomarker in Patients with Clear Cell Renal Cell Carcinoma

Wen-Hao Xu^12BCDEF*, Shen-Nan Shi^23BCDEF, Jun Wang^12BCDEF, Yue Xu^4BDF, Xi Tian^12BCF, Fang-Ning Wan^12BCF, Da-Long Cao^12BCF, Yuan-Yuan Qu^12AEG, Hai-Liang Zhang^12AEG, Ding-Wei Ye^12AEG

DOI: 10.12659/MSM.917754

Med Sci Monit 2019; 25:9458-9470

Authors information Article notes Copyright and License information

Related articles Order reprints Share article Share by email

Export

Export Article Citation

Share via email

Share method:

Via email client program

Send me to my email

Content:

Title, authors, link

Title, authors, link, abstract

The Role of Serine Peptidase Inhibitor Kazal Type 13 (SPINK13) as a Clinicopathological and Prognostic Biomarker in Patients with Clear Cell Renal Cell Carcinoma

Export

Export Article Citation

Export file: The selected type of file is required

Content:

Share via email

Share method:

Content:

Preview:

Your Privacy